Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study
Therapeutic Advances in Medical Oncology
Published online on March 25, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Sacituzumab govitecan (SG), an anti-Trop-2 antibody-drug conjugate (ADC), was approved for metastatic triple-negative breast cancer (mTNBC) with ⩾1 prior therapy and hormone receptor-positive (HoR+) breast cancer progressing on cyclin-dependent ...
Background:Sacituzumab govitecan (SG), an anti-Trop-2 antibody-drug conjugate (ADC), was approved for metastatic triple-negative breast cancer (mTNBC) with ⩾1 prior therapy and hormone receptor-positive (HoR+) breast cancer progressing on cyclin-dependent ...